
The FDA has accepted Shire’s new drug application (NDA) for its dry eye disease drug lifitegrast, putting the treatment on …

Shire has resubmitted its New Drug Application (NDA) to the US FDA for its rejected dry eye syndrome drug lifitegrast. …

The global market for treatments for dry eye syndrome will double in value to an estimated $4.6 billion by 2024, …

This report provides the current prevalent population for dry eye syndrome across seven major markets.It includes data for the USA, …

Shire shares rose 6% today as the company reported new positive Phase III trial data for lifitegrast in the treatment …

Shire has seen an application for its dry eye treatment lifitegrast rejected by the US regulator. The FDA says it …

Shire has acquired Foresight Biotherapeutics for $300 million, as it looks to build its presence in eye diseases. The acquisition …

Shire has achieved mixed results in its attempts to get regulatory approval for two new treatments – bagging a priority …